Abdominal vein thrombosis in essential thrombocythemia

Prevalence, clinical correlates, and prognostic implications

Naseema Gangat, Alexandra P. Wolanskyj, Ayalew Tefferi

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Among 460 consecutive patients with essential thrombocythemia (ET) seen at our institution, 19 cases (4%) of abdominal vein thrombosis (AVT) were documented either at (n = 9) or after (n = 10) diagnosis. Women (P = 0.03) and the young (P = 0.002) were preferentially affected. Accordingly, clinical comparisons were performed among three groups of female patients: those with AVT (group A; n = 17), a control group without AVT but closely matched to group A in terms of age and year of diagnosis (group B; n = 34), and all female patients without AVT (group C; n = 288). As expected from the consequences of AVT-associated portal hypertension and anticoagulant therapy, patients in group A experienced significantly higher rates of hemorrhage, palpable splenomegaly, and anemia. Unexpectedly, however, compared with group B, group A displayed both a higher conversion rate into myelofibrosis/acute leukemia (P = 0.0008) and a shorter median survival (116 vs. 156 months; P = 0.0012). Multivariable analysis including all female patients with ET identified AVT, along with advanced age, leukocytosis, and tobacco use, as an independent risk factor for inferior survival. Groups A, B, and C did not differ in either JAK2V617F mutational frequency or incidence of non-abdominal thrombosis. We conclude that AVT in ET is a marker of aggressive disease biology.

Original languageEnglish (US)
Pages (from-to)327-333
Number of pages7
JournalEuropean Journal of Haematology
Volume77
Issue number4
DOIs
StatePublished - Oct 2006

Fingerprint

Essential Thrombocythemia
Veins
Thrombosis
Primary Myelofibrosis
Survival
Splenomegaly
Leukocytosis
Tobacco Use
Portal Hypertension
Anticoagulants
Anemia
Leukemia
Research Design
Hemorrhage
Control Groups
Incidence

Keywords

  • Budd-Chiari syndrome
  • Hepatic vein thrombosis
  • Leukemic transformation
  • Portal vein thrombosis
  • Prognosis
  • Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Abdominal vein thrombosis in essential thrombocythemia : Prevalence, clinical correlates, and prognostic implications. / Gangat, Naseema; Wolanskyj, Alexandra P.; Tefferi, Ayalew.

In: European Journal of Haematology, Vol. 77, No. 4, 10.2006, p. 327-333.

Research output: Contribution to journalArticle

@article{55751497678c47daa229cccf0a817255,
title = "Abdominal vein thrombosis in essential thrombocythemia: Prevalence, clinical correlates, and prognostic implications",
abstract = "Among 460 consecutive patients with essential thrombocythemia (ET) seen at our institution, 19 cases (4{\%}) of abdominal vein thrombosis (AVT) were documented either at (n = 9) or after (n = 10) diagnosis. Women (P = 0.03) and the young (P = 0.002) were preferentially affected. Accordingly, clinical comparisons were performed among three groups of female patients: those with AVT (group A; n = 17), a control group without AVT but closely matched to group A in terms of age and year of diagnosis (group B; n = 34), and all female patients without AVT (group C; n = 288). As expected from the consequences of AVT-associated portal hypertension and anticoagulant therapy, patients in group A experienced significantly higher rates of hemorrhage, palpable splenomegaly, and anemia. Unexpectedly, however, compared with group B, group A displayed both a higher conversion rate into myelofibrosis/acute leukemia (P = 0.0008) and a shorter median survival (116 vs. 156 months; P = 0.0012). Multivariable analysis including all female patients with ET identified AVT, along with advanced age, leukocytosis, and tobacco use, as an independent risk factor for inferior survival. Groups A, B, and C did not differ in either JAK2V617F mutational frequency or incidence of non-abdominal thrombosis. We conclude that AVT in ET is a marker of aggressive disease biology.",
keywords = "Budd-Chiari syndrome, Hepatic vein thrombosis, Leukemic transformation, Portal vein thrombosis, Prognosis, Survival",
author = "Naseema Gangat and Wolanskyj, {Alexandra P.} and Ayalew Tefferi",
year = "2006",
month = "10",
doi = "10.1111/j.1600-0609.2006.00715.x",
language = "English (US)",
volume = "77",
pages = "327--333",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Abdominal vein thrombosis in essential thrombocythemia

T2 - Prevalence, clinical correlates, and prognostic implications

AU - Gangat, Naseema

AU - Wolanskyj, Alexandra P.

AU - Tefferi, Ayalew

PY - 2006/10

Y1 - 2006/10

N2 - Among 460 consecutive patients with essential thrombocythemia (ET) seen at our institution, 19 cases (4%) of abdominal vein thrombosis (AVT) were documented either at (n = 9) or after (n = 10) diagnosis. Women (P = 0.03) and the young (P = 0.002) were preferentially affected. Accordingly, clinical comparisons were performed among three groups of female patients: those with AVT (group A; n = 17), a control group without AVT but closely matched to group A in terms of age and year of diagnosis (group B; n = 34), and all female patients without AVT (group C; n = 288). As expected from the consequences of AVT-associated portal hypertension and anticoagulant therapy, patients in group A experienced significantly higher rates of hemorrhage, palpable splenomegaly, and anemia. Unexpectedly, however, compared with group B, group A displayed both a higher conversion rate into myelofibrosis/acute leukemia (P = 0.0008) and a shorter median survival (116 vs. 156 months; P = 0.0012). Multivariable analysis including all female patients with ET identified AVT, along with advanced age, leukocytosis, and tobacco use, as an independent risk factor for inferior survival. Groups A, B, and C did not differ in either JAK2V617F mutational frequency or incidence of non-abdominal thrombosis. We conclude that AVT in ET is a marker of aggressive disease biology.

AB - Among 460 consecutive patients with essential thrombocythemia (ET) seen at our institution, 19 cases (4%) of abdominal vein thrombosis (AVT) were documented either at (n = 9) or after (n = 10) diagnosis. Women (P = 0.03) and the young (P = 0.002) were preferentially affected. Accordingly, clinical comparisons were performed among three groups of female patients: those with AVT (group A; n = 17), a control group without AVT but closely matched to group A in terms of age and year of diagnosis (group B; n = 34), and all female patients without AVT (group C; n = 288). As expected from the consequences of AVT-associated portal hypertension and anticoagulant therapy, patients in group A experienced significantly higher rates of hemorrhage, palpable splenomegaly, and anemia. Unexpectedly, however, compared with group B, group A displayed both a higher conversion rate into myelofibrosis/acute leukemia (P = 0.0008) and a shorter median survival (116 vs. 156 months; P = 0.0012). Multivariable analysis including all female patients with ET identified AVT, along with advanced age, leukocytosis, and tobacco use, as an independent risk factor for inferior survival. Groups A, B, and C did not differ in either JAK2V617F mutational frequency or incidence of non-abdominal thrombosis. We conclude that AVT in ET is a marker of aggressive disease biology.

KW - Budd-Chiari syndrome

KW - Hepatic vein thrombosis

KW - Leukemic transformation

KW - Portal vein thrombosis

KW - Prognosis

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=33748355823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748355823&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2006.00715.x

DO - 10.1111/j.1600-0609.2006.00715.x

M3 - Article

VL - 77

SP - 327

EP - 333

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 4

ER -